Prolonged cetuximab treatment promotes p27(Kip1)-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma

Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment are limited. In this study, the long-term cellular outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuyama, Kohei, Suzuki, Keiji, Naruse, Tomofumi, Tsuchihashi, Hiroki, Yanamoto, Souichi, Kaida, Atsushi, Miura, Masahiko, Umeda, Masahiro, Yamashita, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933308/
https://www.ncbi.nlm.nih.gov/pubmed/33664437
http://dx.doi.org/10.1038/s41598-021-84877-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933308/
https://www.ncbi.nlm.nih.gov/pubmed/33664437
http://dx.doi.org/10.1038/s41598-021-84877-4

Ejemplares similares